Literature DB >> 11206358

Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures.

V Gangji1, T Appelboom.   

Abstract

Pamidronate, a bisphosphonate analogue has been evaluated in a retrospective study for its analgesic effect on chronic back pain due to vertebral fractures in 26 patients suffering from senile osteoporosis or glucocorticoid-induced osteoporosis. Sixty milligrams of pamidronate was administered intravenously every 3 months for one year. After three months of treatment, the pain score fell from 3.2 +/- 0.1 to 1.2 +/- 0.2 in both groups. In conclusion, intravenous pamidronate seems to be a valuable treatment for chronic back pain due to osteoporotic vertebral fractures.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 11206358     DOI： 10.1007/s100670050099

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  22 in total

1.  An unusual cause of spinal bone loss detected by DXA scanning.

Authors:  H Davies; M W J Davie
Journal:  Osteoporos Int       Date:  2012-03-30       Impact factor: 4.507

2.  Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study.

Authors:  M Laroche; S Cantogrel; B Jamard; A Constantin; L Zabraniecki; A Cantagrel; B Mazières
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

3.  High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman.

Authors:  Christian Muschitz; Paul Roschger; Janina Patsch; Isabella Pollhammer; Bruno Koller; Klaus Klaushofer; Heinrich Resch
Journal:  Wien Med Wochenschr       Date:  2007

4.  An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy.

Authors:  Liron Caplan; Cory B Pittman; Angelique L Zeringue; Jeffrey F Scherrer; Kent R Wehmeier; Francesca E Cunningham; Seth A Eisen; Jay R McDonald
Journal:  Mayo Clin Proc       Date:  2010-03-15       Impact factor: 7.616

5.  N-formyl-methionyl-leucyl-phenylalanine (fMLP) promotes osteoblast differentiation via the N-formyl peptide receptor 1-mediated signaling pathway in human mesenchymal stem cells from bone marrow.

Authors:  Min Kyoung Shin; Young Hoon Jang; Hyun Jung Yoo; Dong Woo Kang; Mi Hee Park; Mi Kyoung Kim; Ju Hyun Song; Sang Doo Kim; Gyesik Min; Hyung Keun You; Kang-Yell Choi; Yoe-Sik Bae; Do Sik Min
Journal:  J Biol Chem       Date:  2011-03-03       Impact factor: 5.157

6.  Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato; Mitsuyoshi Uzawa
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

7.  The neurological safety of epidural pamidronate in rats.

Authors:  Pyung Bok Lee; Yong Chul Kim; Chul Joong Lee; Hye Young Shin; Seung Yun Lee; Jong Cook Park; Yun Suk Choi; Chong Soo Kim; Sang Hyun Park
Journal:  Korean J Pain       Date:  2010-05-31

8.  Management of osteoporotic vertebral fractures.

Authors:  Yannis Dionyssiotis
Journal:  Int J Gen Med       Date:  2010-07-21

Review 9.  Pamidronate treatment in rheumatology practice: a comprehensive review.

Authors:  Gleb Slobodin; Itzhak Rosner; Joy Feld; Doron Rimar; Michael Rozenbaum; Nina Boulman; Majed Odeh
Journal:  Clin Rheumatol       Date:  2009-08-19       Impact factor: 2.980

10.  Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance.

Authors:  Takuo Fujita; Mutsumi Ohue; Yoshio Fujii; Akimitsu Miyauchi; Yasuyuki Takagi
Journal:  J Bone Miner Metab       Date:  2009-02-13       Impact factor: 2.626
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.